318 related articles for article (PubMed ID: 17804840)
1. Sidelining safety--the FDA's inadequate response to the IOM.
Smith SW
N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
[No Abstract] [Full Text] [Related]
2. Congress responds to the IOM drug safety report--in full.
Psaty BM; Korn D
JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
[No Abstract] [Full Text] [Related]
3. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
Psaty BM; Meslin EM; Breckenridge A
JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
[No Abstract] [Full Text] [Related]
4. The FDA and the IOM report.
Galson SK
N Engl J Med; 2007 Dec; 357(24):2520-1; author reply 2521-2. PubMed ID: 18077820
[No Abstract] [Full Text] [Related]
5. The report of the Institute of Medicine on drug safety.
Somberg J
Am J Ther; 2007; 14(1):1-2. PubMed ID: 17303967
[No Abstract] [Full Text] [Related]
6. IOM: congress must reform FDA to improve drug safety.
Young D
Am J Health Syst Pharm; 2006 Nov; 63(21):2032, 2034. PubMed ID: 17057032
[No Abstract] [Full Text] [Related]
7. Protecting the health of the public--Institute of Medicine recommendations on drug safety.
Psaty BM; Burke SP
N Engl J Med; 2006 Oct; 355(17):1753-5. PubMed ID: 17030843
[No Abstract] [Full Text] [Related]
8. Institute of Medicine, Congress seek solutions to FDA's safety woes through reform, funding.
Finkelstein JB
J Natl Cancer Inst; 2007 Jan; 99(2):104-7. PubMed ID: 17227990
[No Abstract] [Full Text] [Related]
9. Ethical considerations in studying drug safety--the Institute of Medicine report.
Mello MM; Goodman SN; Faden RR
N Engl J Med; 2012 Sep; 367(10):959-64. PubMed ID: 22913661
[No Abstract] [Full Text] [Related]
10. The Institute of Medicine's report on drug safety: constructive and ambitious, but does it go far enough?
Jones JK
Clin Pharmacol Ther; 2007 Feb; 81(2):156-8. PubMed ID: 17259940
[TBL] [Abstract][Full Text] [Related]
11. IOM advises FDA on ethics in postmarket safety trials.
Kuehn BM
JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
[No Abstract] [Full Text] [Related]
12. IOM: overhaul drug safety monitoring.
Kuehn BM
JAMA; 2006 Nov; 296(17):2075-6. PubMed ID: 17077364
[No Abstract] [Full Text] [Related]
13. Reply to "Can the Institute of Medicine review the FDA?".
Fineberg HV
Nat Med; 2005 Jun; 11(6):589. PubMed ID: 15937463
[No Abstract] [Full Text] [Related]
14. The future of drug safety: what the IOM report may mean to the emergency department.
Berger E
Ann Emerg Med; 2007 Feb; 49(2):193-5. PubMed ID: 17245837
[No Abstract] [Full Text] [Related]
15. The Institute of Medicine report on the FDA: where is the science?
Philipson T; Jena AB; Sun E
Health Econ; 2007 Mar; 16(3):219-21. PubMed ID: 17315264
[No Abstract] [Full Text] [Related]
16. The future of drug safety.
Breckenridge A
Clin Pharmacol Ther; 2007 Feb; 81(2):161-3. PubMed ID: 17259942
[TBL] [Abstract][Full Text] [Related]
17. IOM urges FDA to be more aggressive in monitoring safety of approved drugs.
Kuehn BM
JAMA; 2012 Jun; 307(23):2475-6. PubMed ID: 22797430
[No Abstract] [Full Text] [Related]
18. Science and regulation. FDA's approach to regulation of products of nanotechnology.
Hamburg MA
Science; 2012 Apr; 336(6079):299-300. PubMed ID: 22517845
[No Abstract] [Full Text] [Related]
19. Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference.
Crawford LM
Food Drug Law J; 2005; 60(2):99-102. PubMed ID: 16097087
[No Abstract] [Full Text] [Related]
20. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
